[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospital, Strasbourg, France\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":664},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,249,0,25,[9,46,78,104,129,169,197,221,246,268,289,309,335,364,387,416,435,459,478,499,530,559,590,615,637],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100053832","impact-of-an-optimized-omega-3-formulation-on-inflammation-and-endothelial-dysfunction-in-pulmonary-arterial-hypertension-100053832",false,"NCT07697235","Impact of an Optimized Omega-3 Formulation on Inflammation and Endothelial Dysfunction in Pulmonary Arterial Hypertension","OMEGA-PAH","Inclusion Criteria:\n\n* Men or women between the ages of 18 and 75;\n* Idiopathic, hereditary, drug-induced, or anorexigen-induced PAH, or PAH associated with connective tissue disease;\n* Stable PAH treatment for at least 90 days;\n* Subjects capable of understanding the objectives and risks associated with the study and of providing dated and signed informed consent;\n* Subjects enrolled in a health insurance plan;\n* Subjects who have signed an informed consent form;\n* For women of childbearing age: negative pregnancy test at the screening\u002Finclusion visit; effective contraception\\* throughout the study (recommended in PAH)\n\n  * Effective and accepted methods of contraception during the study (subject, partner): oral contraceptive pill, intrauterine device (IUD), condom (male or female). Patients who practice total abstinence do not need to use contraception.\n\nExclusion criteria:\n\n* Patients treated with Omacor®;\n* Daily consumption of fish oil or fish oil-based dietary supplements (omega-3);\n* Hypersensitivity or allergy to fish, shellfish, peanuts, soy, corn oil, or coconut oil;\n* Anticoagulant therapy at therapeutic doses;\n* Cardiac decompensation within the month prior to enrollment;\n* Other causes of pulmonary hypertension (groups 2, 3, 4, or 5);\n* Persistent atrial fibrillation (AF);\n* Left ventricular ejection fraction \\\u003C 45% on echocardiography;\n* Recent episode of pulmonary embolism, within the past 6 months;\n* Myocardial infarction or placement of a coronary stent within the month prior to enrollment;\n* eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²;\n* Malignant disease (not considered in remission);\n* Severe sepsis;\n* Participation in another clinical trial within the previous 3 months;\n* Subjects under legal guardianship, conservatorship, or curatorship","ALL","18 Years","75 Years",{"count":21,"type":22},22,"ESTIMATED","INTERVENTIONAL",[25],"NA","The objective of this research project is to evaluate the biological effects of long-chain omega-3 supplementation, administered in an optimized, high-purity formulation (EPA:DHA 6:1, \\>95% v\u002Fv), as an adjunct to standard-of-care treatment in patients with pulmonary arterial hypertension (PAH).\n\nThe expected results are confirmation in humans of our preliminary data, namely a beneficial effect on systemic inflammation and pulmonary endothelial dysfunction in PAH. If our hypothesis is confirmed, omega-3s could constitute a complementary nutritional approach to current PAH therapies, subsequently requiring validation through a larger-scale, randomized, controlled study.",[28],"PAH",[30,31,32,33],"pulmonary arterial hypertension","inflammation","peripheral circulating cells","omega-3","NOT_YET_RECRUITING","2026-07-08",{"date":37,"type":38},"2026-07-13","ACTUAL",{"date":40,"type":22},"2026-07",{"date":42,"type":22},"2030-03",{"name":44,"class":45},"University Hospital, Strasbourg, France","OTHER",{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100640941","evaluating-how-red-light-therapy-applied-to-the-head-affects-symptoms-daily-life-and-brain-activity-in-people-with-dementia-with-lewy-bodies-100640941","NCT07602296","Evaluating How Red-light Therapy Applied to the Head Affects Symptoms, Daily Life, and Brain Activity in People With Dementia With Lewy Bodies","Effect of Transcranial Photobiomodulation on Clinical Symptoms, Quality of Life and Cerebral Connectivity Modifications in Dementia With Lewy Bodies","LewyLIGHT","Inclusion criteria:\n\n* Man or woman, 50 years or older\n* Probable DLB diagnosed according to the criteria of McKeith et al., 2017, or the criteria of McKeith et al., 2020 for prodromal DLB\n* Score on the Mini Mental State Examination (MMSE; Folstein et al., 1983) ≥ 18\u002F30 at their last medical visit\n* Good mastery of the French language\n* Accompanied by a caregiver or a person able to provide information about them (interview, by telephone).\n* Able to understand the objectives and risks associated with the research and to give informed consent, dated and signed\n* Covered by a social health insurance plan\n* Having a head circumference between 54 and 62 cm.\n\nExclusion criteria:\n\n* Not able to understand the objectives and risks related to research and to give informed consent\n* Presence of another neurological disorder, including but not limited to brain tumors, stroke with potential cognitive impairment, or diagnosis of another progressive neurological disease (e.g., Alzheimer's disease, Parkinson's disease, etc.), and as determined by the investigator\n* Having an MMSE score \\\u003C 18 at the screening visit\n* Unable to undergo a brain MRI due to medical reasons\n* Participants whose follow-up would likely be disrupted during the study period (e.g., due to planned relocation or other reasons)\n* Insufficient proficiency of the French language\n* Participants experiencing an emergency of life-threatening situation\n* Alone, without a caregiver present\n* Participants presenting with a head\u002Fscalp injury\n* Participants with a silicone allergy\n* Participants with cranial\u002Fskull shape abnormalities\n* Participants with a head circumference outside the range of 54-62 cm\n* Participants requiring life support, continuous monitoring, and\u002For implanted medical devices (AIMD)\n* Participants taking the antiepileptic Keppra (Levetiracetam)\n* Participants whose anticholinesterase treatments have been changed within the past 2 months\n* Participants whose antipsychotic treatments have been changed within the last 15 days\n* Pregnant or breastfeeding women","50 Years",{"count":56,"type":22},40,[25],"Dementia with Lewy bodies (DLB) is a neurodegenerative disease diagnosed primarily based on the presence of cognitive decline, which may include difficulties with memory, attention, and more. Additionally, at least two of the following symptoms are needed for a probable diagnosis of DLB, and at least one for a possible DLB diagnosis (McKeith et al. 2017 and 2020):\n\n* Fluctuations in cognition, attention, and\u002For alertness\n* Visual hallucinations\n* Spontaneous parkinsonism\n* REM sleep behavior disorder\n\nPatients with DLB can experience cognitive deficits that can fluctuate and can vary for each patient. These may include deficits in memory, executive functions (planning and organizing), attention, visual processing, and language.\n\nThis study aims to evaluate the effect of red-light therapy, delivered using a helmet that contains small LED lights, in patients with DLB.\n\nParticipants' cognitive functions, clinical symptoms, quality of life and functional cerebral connectivity will be evaluated before starting therapy and again after three and six months of twice daily therapy use. As DLB also indirectly affects caregivers, the caregiver's quality of life and burden will also be evaluated before and at three and six months of therapy use by the participant.\n\nThe study's inclusion period is 24 months and the duration of participation for each patient is 8 months (+\u002F-10 days) maximum.",[60,61],"Photobiomodulation","Dementia With Lewy Bodies",[63,64,65,66,67,68],"Photobiomodulation (PBM)","Dementia with Lewy bodies (DLB)","Cognitive functions","Clinical symptoms","Quality of life","Cerebral connectivity","2026-06-18",{"date":71,"type":38},"2026-06-23",{"date":73,"type":22},"2026-06",{"date":75,"type":22},"2029-03",{"name":44,"class":45},1,{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":87,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":4},"100641397","evaluation-of-a-structured-hospital-community-care-follow-up-based-on-perceived-quality-of-care-after-surgery-aimed-at-reducing-persistent-opioid-use-in-primary-care-a-pragmatic-randomized-controlled-trial-100641397","NCT07659730","Evaluation of a Structured Hospital-Community Care Follow-up Based on Perceived Quality of Care After Surgery, Aimed at Reducing Persistent Opioid Use in Primary Care: a Pragmatic Randomized Controlled Trial","OPIOID CITY FR","Inclusion Criteria:\n\n* Male or female\n* Adult patient, with no upper age limit\n* Undergoing scheduled or unscheduled surgery in a center participating in the research\n* Subject affiliated to a social health insurance scheme\n* Subject able to understand the objectives and risks related to the research and to give informed consent, dated and signed\n\nExclusion Criteria:\n\n* Inability to administer the mQoR-15f questionnaire (cognitive disorders, language barrier)\n* Patient who has already received previous follow-up by the OPTIMISTE team\n* Patient enrolled in a therapeutic trial that may affect post-operative recovery quality.\n* Pregnant or breastfeeding woman\n* Inability to provide the subject with informed information (subject in an emergency situation, difficulties in understanding, etc.)\n* Subject under legal protection, guardianship or curatorship",{"count":86,"type":22},772,[25],"The OPTIMISTE program is based on a structured postoperative follow-up centered on patients' subjective perception of recovery using validated Patient Reported Outcome Measures (PROMs), including the mQoR-15f score. Follow-up is delivered by specifically trained nurses and embedded in a decompartmentalized care model combining in-person and remote interactions, integrating hospital teams and primary care professionals within a coordinated pathway.\n\nOPTIMISTE was recently evaluated in a multicenter randomized controlled trial, the SUPPORT study (NCT06182254), which included 280 patients. The study demonstrated a significant impact of PROM-based follow-up on perceived recovery at postoperative day 35, and more importantly, an approximately 50% reduction in the proportion of patients with persistent opioid use at that time point. Although this was a secondary endpoint, the findings suggest that active postoperative monitoring centered on patient-reported outcomes and rapidly relayed to community care providers represents a major lever for preventing opioid misuse after surgery.\n\nHowever, these results require further confirmation and refinement. First, the effect on persistent opioid consumption needs to be validated as a primary endpoint. Second, despite the benefit observed, more than 12% of patients in the intervention group still exhibited persistent opioid use five weeks after surgery, compared with 21% in the control group. This residual persistence, although reduced, remains clinically concerning and indicates that the current OPTIMISTE model does not yet fully prevent unanticipated prolonged opioid exposure.\n\nThe hypothesis of the present protocol is that the effectiveness of OPTIMISTE in reducing postoperative persistent opioid use can be strengthened through earlier, more individualized and primary-care-driven management. This enhancement relies on better mobilization of community healthcare professionals - general practitioners, community nurses and pharmacists - supported by digital health tools and reinforced coordination channels such as secure platforms, teleconsultations and structured transmission of PROM scores.\n\nBy systematically integrating primary care providers into longitudinal postoperative follow-up guided by PROMs, the protocol aims to improve therapeutic responsiveness, reduce unjustified prolonged prescriptions and promote early tapering when clinically appropriate. The objective is to optimize hospital-community coordination in order to amplify the impact of the OPTIMISTE pathway on patient-perceived recovery and opioid stewardship.\n\nUltimately, this research seeks to demonstrate that strengthening the role of primary care, combined with fine-grained assessment of patient-reported recovery, represents an effective, ethical and scalable strategy to improve the quality, safety and efficiency of postoperative care pathways while sustainably reducing persistent opioid use at both individual and population levels.",[90,91],"Perioperatoire Medicine","Surgery",[93,91,94,95],"Perioperative","Patient Reported Outcomes Mesuares (PROMs)","persistent opioid use","2026-06-15",{"date":98,"type":38},"2026-06-22",{"date":100,"type":22},"2026-07-02",{"date":102,"type":22},"2029-12-01",{"name":44,"class":45},{"id":105,"slug":106,"hasResults":12,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":12,"sex":17,"minAge":112,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":23,"phases":116,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":77},"100531504","pain-relief-in-premature-newborns-through-maternal-intervention-during-venipuncture-100531504","NCT06200662","Pain Relief in Premature Newborns Through Maternal Intervention During Venipuncture","Pain Relief in Premature Newborns Through Maternal Intervention During Venipuncture: Effectiveness, Experiences of Parents and Carers","PREMAMANDOL","Inclusion Criteria:\n\n* Very premature babies born before the gestational age (GA) of 32 weeks of amenorrhoea (SA) whose corrected age (CA) does not exceed 34 SA at the time of their participation.\n* NN requiring close biological monitoring by a PV.\n* Hospitalised in the NN medicine and intensive care unit at Strasbourg hospital.\n* Consent obtained from both holders of parental authority.\n* Person covered by a social health insurance scheme.\n\nExclusion Criteria:\n\n* Any known malformation affecting one or more organs.\n* Cerebral lesions discovered o n cerebral ultrasound (intraventricular haemorrhage grade \\> 2, periventricular leukomalacia).\n* Unstable clinical state as judged by the investigator and the medical team.\n* Transfer to another hospital centre expected before the end of the study period.\n\n  * Mother: Minor. Deprived of liberty by judicial or administrative decision. Under legal protection. Severe psychological pathology. Drug addiction. Difficulty understanding and\u002For reading the language.\n\nFrench.","32 Weeks","34 Weeks",{"count":115,"type":22},48,[25],"Extremely premature newborn infants (ELNs) admitted to hospital are exposed to stressful and painful stimuli, and often to maternal separation, which can affect their long-term neurological development. Child- and family-centred developmental care (CFDC) in neonatology aims to adapt the hospital environment to the needs of the child, support the continued presence of the family and help to improve their future.\n\nSpecific assessment and appropriate analgesic treatment are therefore priorities for preserving the well-being and cerebral development of this population, which is particularly vulnerable to pain. Pain relief for certain procedures necessary for the care of newborn babies, such as venipuncture (PV), remains inadequate. Venipuncture is a common procedure in the first few weeks of life for very premature newborns. Its analgesic treatment is based on non-medicinal strategies largely carried out in the nurse's own role: non-nutritive suctioning combined with the administration of a sugar solution and wrapping. In line with the SDCEF philosophy, and reinforced by the \"zero separation\" concept, parental involvement in the treatment of their newborn's pain becomes natural and fundamental. A number of studies have shown the benefits of parents' presence and participation through specific isolated analgesic actions. Skin- to-skin contact (PAP) is one of these and has multiple benefits for the newborn. However, in practice, when a PV is necessary for a very premature baby, its use as a pain-relieving strategy is hampered by a number of obstacles. As NN are naturally oriented towards the maternal voice, using it is a new approach to analgesia. In an innovative study carried out in a single centre, direct maternal voice contact, in addition to the usual non- pharmacological analgesic strategies, reduced the NN's pain, without completely eliminating it during heel sampling (a skin incision known to be more painful than a PV). This analgesic strategy should therefore be combined with other non-pharmacological strategies, taking advantage of all maternal skills.",[119],"Premature Newborns","RECRUITING","2026-06-05",{"date":123,"type":38},"2026-06-09",{"date":125,"type":38},"2024-02-22",{"date":127,"type":22},"2028-02-07",{"name":44,"class":45},{"id":130,"slug":131,"hasResults":12,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":137,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":23,"phases":140,"briefSummary":141,"conditions":142,"keywords":149,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":163,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":77},"100469490","regulating-emotions-and-behaviors-after-brain-injury-100469490","NCT05393492","Regulating Emotions and Behaviors After Brain Injury","Dialectical Behavior Therapy for Challenging Behaviors and Emotional Distress After Acquired Brain Injury : a Pilot Study","GREMO-LCA","Eligibility Criteria: \\* (Limit: 15,000 characters)\n\nSummary criteria for participant selection.\n\nMain eligibility criteria\n\nGREMO patients :\n\n* Inclusion criteria:\n\n  * Persons with acquired brain injury regardless of the type or location of the injury\n  * Age between 18 and 68\n  * Over 18 months since the acquired brain injury (or 6 month if mild traumatic brain injury)\n  * Challenging behaviors or emotional dysregulation or high level of anxiety \u002F depression or family's complaints about emotional dysregulation\n  * Secondary or exacerbated by an acquired brain injury\n  * Causing important suffering for themselves or their families\n  * Being affiliated to a social security\n  * Fluent in French\n  * Being able to understand goals and risks and to give a dated and signed consent\n* Exclusion criteria:\n\n  * Clinically evident severe lack of insight, lack of abstract reasoning, or severe anosognosia\n  * Patients without any complaints\n  * Severe cognitive impairments, aphasia or intellectual impairments that doesn't allow to understand DBT skills, questionnaires or group intreactions\n  * Non fluent in French\n  * Associated brain degenerative disease\n  * Cancerous brain injury with uncertain progression\n  * Non-stabilized psychotic disorder\n  * Following a third wave cognitive behavioral therapy during the research study (for example : acceptance and commitment therapy)\n\nControls without brain injury\n\n* Inclusion criteria :\n\n  * Being 18 years old or more\n  * Without brain injury\n* Exclusion criteria :\n\n  * Non fluent in French\n  * History of brain injury or brain disease\n  * History of psychiatric disorder\n  * Personality disorder\n  * GREMO patient's family member living together\n  * Psychologist, neuropsychologist or people with an emotional regulation knowledge linked to their profession\n  * Being under guardianship or curatorship\n  * Being pregnant or breastfeeding\n\nGREMO patients' family members\n\n* Inclusion criteria :\n\n  * Being 18 years old or more\n  * GREMO patient's family member\n  * Living with a GREMO patient\n  * Agreeing to rate an emotion-behavior-skills diary cards\n* Exclusion criteria :\n\n  * GREMO patient's refusal for their family member to participate\n  * Non fluent in French\n  * Brain injury or brain disease\n  * Major lack of insight\n  * Being under trusteeship or curatorship\n\nQualitative research ABI patients and families\n\n* Inclusion criteria :\n\n  * Person with ABI attending the same medico-social service as GREMO patients\n  * Ineligible for GREMO patients group (participation refusal, major insight difficulty…)\n  * Agreeing to talk about their free will or spirituality\n* Exclusion criteria :\n\n  * Aphasia or dysarthria not allowing understandable recording\n  * Impossibility to understand oral questions\n  * Non fluent in French",true,{"count":139,"type":22},77,[25],"After acquired brain injury (ABI), persons can experience emotional and behavioral difficulties, that can be painful both for the person and his\u002Fher family. This clinical study aims at measuring the effectiveness of a third wave cognitive behavioral therapy called \"dialectical behavior therapy\" (DBT). DBT aims at teaching persons emotion regulation skills, interpersonal effectiveness skills, mindfulness and distress tolerance skills through group and individual sessions.\n\nThe study's hypothesis is that DBT, in an adapted format for persons with ABI can lead to\n\n* a better quality of life, emotional and behavioral regulation, and self-esteem\n* decrease in problematic behaviors\n* progress in life goals\n* increase post traumatic growth and spirituality\n* better family functioning and lesser burden for care givers\n* experiencing more emotions and more free will\n\n  45 persons with an ABI sustained more than 18 month back, will follow a 3 phases, follow-up with care as usual for 5 months, followed by 5 months of DBT, followed by 5 months of care as usual + DBT monthly sessions.\n\nSelf- and family-questionnaire will explore quality of life, emotional regulation, self-esteem, stress, anxiety, cognitive difficulties, family functioning and coping, post traumatic growth and spirituality and will be compared across the 3 phases. Results will be analyzed at a group level but also at an individual level (each patient separately) to test for decrease in unwanted behaviors and at a dyadic level (the person and his\u002Fher spouse) to test for the mutual effect of regulating emotions. Persons' memories will by analyzed at 3 time points by a linguistic analysis, and experience of free will after ABI will be analyzed by transcribed narratives of participants.",[143,144,145,146,147,148],"Acquired Brain Injury","Stroke\u002F Cerebrovascular Accident (Ischemic or Hemorrhagic)","Brain Tumor (After Recovery)","Encephalitis","Cerebral Anoxia","Meningitis",[150,151,152,153,154,155,156,157,158,159,160,161,162],"brain injury","dialectical behavior therapy","emotions","emotional dysregulation","behavioral disorders","spirituality","challenging behaviors","linguistic markers","emotional distress","family burden","free will","interpretative phenomenological analysis","single-case experimental design",{"date":123,"type":38},{"date":165,"type":38},"2022-05-19",{"date":167,"type":22},"2028-12",{"name":44,"class":45},{"id":170,"slug":171,"hasResults":12,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":23,"phases":179,"briefSummary":181,"conditions":182,"keywords":185,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":77},"100454358","phase-3-efficacy-of-an-intraoperative-periradicular-application-of-platelet-rich-fibrin-prf-on-the-intensity-of-residual-post-surgical-neuropathic-pain-after-a-surgery-for-disc-herniation-100454358","NCT05196503","Efficacy of an Intraoperative Periradicular Application of Platelet Rich Fibrin (PRF) on the Intensity of Residual Post-surgical Neuropathic Pain After a Surgery for Disc Herniation","Efficacy of Platelet Rich Fibrin in the Prevention of Residual Neuropathic Pain Following Disc Herniation Surgery","NeuroPRF","Inclusion criteria:\n\n* Patient, male or female, \\>18 years old at the time of signing informed consent;\n* Patient for whom a diagnosis of radiculopathy on lumbar disc herniation has been made, and for whom surgery has been scheduled in the Neurosurgery department;\n* Patient affiliated to a social security health insurance scheme;\n* Patient able to understand the objectives and risks of research and to give informed, dated and signed consent;\n* Patient having been informed of the results of the prior medical examination;\n* Women of childbearing age provided that a negative blood pregnancy test is recorded at the inclusion visit and effective contraception used throughout the study.\n\nExclusion criteria:\n\n* Patient with a history of lumbar spinal surgery (multiple herniated discs, herniated disc other than lumbar);\n* Patient with HIV, active cancer, HBV, HCV (verified by interview);\n* Patient on long-term systemic corticosteroid therapy;\n* Patient with an ASA score \\> 3 during the consultation with the anesthesiologist;\n* Inability to give the patient informed information (patient in an emergency or life-threatening situation, difficulties in understanding);\n* Patient in exclusion period (determined by a previous or ongoing study);\n* Subject under safeguard of justice;\n* Subject under curatorship;\n* Pregnancy;\n* Breastfeeding.",{"count":178,"type":22},60,[180],"PHASE3","The prevalence of post-surgical lumbar neuropathic radiculopathy is approximately 30%. Poor response to the treatments recommended for neuropathic pain, namely antidepressants and\u002For gabapentinoids, requires the development of new techniques to prevent this chronic pain. Certain well-tolerated techniques, such as the administration of plasma enriched with platelets and fibrin (PRF), are increasingly used in regenerative medicine for their anti-inflammatory and analgesic properties. Thus, a periradicular intraoperative application of PRF may have an analgesic effect on the intensity of residual postsurgical neuropathic pain after disc herniation surgery.",[183,184],"Neuropathic Pain","Chronic Postsurgical Pain",[186,187,188,189],"Neuropathic pain","Chronic postsurgical pain prevention","Intraoperative platelet rich fibrin","Disc herniation surgery",{"date":191,"type":38},"2026-06-08",{"date":193,"type":38},"2022-02-23",{"date":195,"type":22},"2028-01",{"name":44,"class":45},{"id":198,"slug":199,"hasResults":12,"nctId":200,"briefTitle":201,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":23,"phases":205,"briefSummary":206,"conditions":207,"keywords":212,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":215,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":77},"100452889","efficacy-of-a-personalized-rehabilitation-program-of-facial-involvement-in-systemic-sclerosis-100452889","NCT05177380","Efficacy of a Personalized Rehabilitation Program of Facial Involvement in Systemic Sclerosis","PREVISS","Inclusion Criteria:\n\n* Age ≥ 18 yo\n* Systemic sclerosis according to the 2013 ACR\u002FEULAR (American College of Rheumatology) classification criteria\n* Systemic sclerosis with facial involvement defined by a MHISS score \\> 6\n* Immunosuppressive and\u002For anti-fibrosis treatment stable for at least 1 month\n* Subject able to understand the objectives and risks of research and to give informed consent\n* Subject enrolment in the health insurance scheme\n\nExclusion Criteria:\n\n* Pregnancy\n* Previous participation in a rehabilitation program of facial involvement\n* Patient under legal protection\n* Impossibility to give clear information of subject",{"count":178,"type":22},[25],"Systemic sclerosis is a rare autoimmune disorder characterized by microangiopathy, activation of the immune system, and sclerosis of tissues including the skin. Facial involvement is frequent and disabling. It causes significant functional and aesthetic discomfort, and a major deterioration in quality of life. It results in a loss of suppleness of the skin and subcutaneous tissues, dysfunction of the temporomandibular joint, peribuccal rhagades, microstomia, and dry mouth causing difficulties in mouth opening, feeding, dental care, and weight loss.\n\nFacial involvement in systemic sclerosis can be assessed using the Mouth Handicap in Systemic Sclerosis (MHISS) score, a validated patient questionnaire assessing the functional and aesthetic consequences of systemic sclerosis on the face.\n\nAlthough common and disabling, facial involvement is underestimated and poorly managed. Immunosuppressive and\u002For anti-fibrosis drugs are not very effective. Facial rehabilitation could significantly improve the mouth handicap but facial rehabilitation is not currently performed in standard care in systemic sclerosis patients.\n\nThe aim of the study is to evaluate the efficacy of a personalized rehabilitation program vs standard care in facial involvement of systemic sclerosis patients.",[208,209,210,211],"Systemic Sclerosis","Face","Facial Involvement","Rehabilitation",[209,213,211,214],"Facial involvement","Systemic sclerosis",{"date":191,"type":38},{"date":217,"type":38},"2022-10-13",{"date":219,"type":22},"2029-12",{"name":44,"class":45},{"id":222,"slug":223,"hasResults":12,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":23,"phases":231,"briefSummary":233,"conditions":234,"keywords":4,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":77},"100583868","phase-4-eduction-in-immunosuppressive-regimen-among-kidney-transplant-recipients-patients-admitted-to-the-intensive-care-unit-for-septic-shock-andor-acute-respiratory-failure-100583868","NCT06881927","Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and\u002For Acute Respiratory Failure","Reduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and\u002For Acute Respiratory Failure: a Multicenter, Open-label, Phase IIb Randomized Controlled Trial","REDIS","Inclusion Criteria:\n\n* \\- Adult patients, aged 18 years-old and over,\n* Kidney transplant recipients, with transplantation occurring more than 3 months prior to ICU admission\n* Patients admitted to the ICU in the setting of:\n\n  * Septic shock (sepsis requiring vasopressor support, with or without hyperlactatemia),\n  * And\u002For acute respiratory failure of presumed infectious origin (invasive or non-invasive ventilation, FiO2 greater than or equal to 50%),\n* Patients treated with at least an immunosuppressive bitherapy (including steroids, calcineurin inhibitors, mTOR inhibitors, azathioprine, or mycophenolate mofetil),\n* Patients affiliated with a social health insurance protection scheme,\n* Patients able of understanding the objectives and risks related to the research and providing a dated and signed informed consent. If patient is unable to consent: consent from relatives will be searched, and if absent, an emergency procedure will be process.\n* Women of childbearing potential, provided they have a negative blood pregnancy test on the day of the inclusion visit.\n\nExclusion Criteria:\n\n* Minor patients,\n* Patients unable to consent: under legal protection measures, patients deprived of liberty,\n* Kidney transplant recipients treated with Belatacept due to the persistent effect of Belatacept, it is not possible to modulate this treatment in a short term period,\n* Patients with severe chronic graft dysfunction (glomerular filtration rate \\\u003C 20 ml\u002Fmin\u002F1.73m² according to the CKD-EPI formula in the month prior to admission),\n* Transplant renal recipients who have already resumed RRT (hemodialysis or peritoneal dialysis),\n* Multi-organ transplant recipients,\n* Pregnant women",{"count":230,"type":22},212,[232],"PHASE4","Kidney transplantation is the treatment of choice for end-stage chronic kidney disease. Kidney transplantation is at the first rank of solid organ transplantation in France, with 3,376 grafts performed in 2022. Immunosuppressive therapy, required to prevent graft rejection, exposes graft recipients to complications related to decreased immunity, including opportunistic infections and neoplastic complications.\n\nAfter the earlt post-transplantation period, up to 10% of kidney transplant recipients will require admission to the intensive care unit (ICU). The main reasons for admission are septic shock and acute hypoxemic respiratory failure. ICU stay has a significant impact on these patients with a mortality rate reaching 40%, that remains increased even after ICU discharge. Furthermore, an impact on graft function has been demonstrated, with deterioration of graft function in 1\u002F3 of patients, and among those, up to one in two will require resumption of renal replacement therapy (RRT).\n\nAlthough the occurrence of septic shock or acute respiratory failure related to an infection is more common and severe, the optimal management strategy for immunosuppressors is not defined in kidney transplant recipients admitted to the ICU in those settings.\n\nMaintain a high level of immunosuppressive therapies may hinder the recovery from the acute critical condition. Furthermore, these treatments have a narrow therapeutic index; for instance, the management of calcineurin inhibitors is challenging in the ICU due to pharmacodynamic changes associated with the acute situation (distribution volume, organ failure) and the numerous potential drug interactions that carry inherent risks of overdose.\n\nthe investigators hypothesize that a reduction in the level of immunosuppressive treatments could promote recovery in kidney transplant recipients admitted to the ICU for septic shock and\u002For acute hypoxemic respiratory failure, without adversely affecting the risk of rejection or long-term renal prognosis.",[235,236,237,238],"Sepsis and Septic Shock","Acute Respiratory Failure","Kidney Transplant Recipients","Immunosuppressive Agents","2026-06-03",{"date":121,"type":38},{"date":242,"type":38},"2026-05-11",{"date":244,"type":22},"2029-06-01",{"name":44,"class":45},{"id":247,"slug":248,"hasResults":12,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":252,"eligibilityCriteria":253,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":256,"phases":4,"briefSummary":257,"conditions":258,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":264,"completionDateStruct":265,"leadSponsor":267,"locationsCount":77},"100637629","early-diagnosis-of-septic-dic-100637629","NCT07630415","EARLY DIAGNOSIS OF SEPTIC DIC","OPTIMIZATION AND CLINICAL VALIDATION OF AN INNOVATIVE TEST FOR THE EARLY DIAGNOSIS OF SEPTIC DIC VIA AN AUTOMATION INTEGRATING ARTIFICIAL INTELLIGENCE","EASY-DIC","Inclusion Criteria:\n\n* Male or female ≥ 18 years old\n* Patient admitted to intensive care for septic shock\n* Patient affiliated with a social security scheme or having rights\n* No objection from the patient or a relative in case the patient is not able to express consent, or inclusion under emergency procedure in case the patient is not able to express their opinion and no relative of the patient is reachable.\n\nExclusion Criteria:\n\n* Moribund patient on the day of inclusion\n* Child-Pugh C cirrhosis\n* Neutropenia (\\\u003C500 mm3)\n* Patient under legal protection\n* Patient under guardianship or curatorship\n* Pregnancy\u002F Breastfeeding",{"count":255,"type":22},492,"OBSERVATIONAL","Disseminated Intravascular Coagulation is a severe complication of septic shock, associated with high mortality, whose diagnosis relies on complex scores that are rarely used in practice. Preliminary studies have shown that increased neutrophil fluorescence is associated with Disseminated Intravascular Coagulation and could reflect NETosis, a key mechanism of immunothrombosis. This study aims to validate neutrophil fluorescence measured on the SthemA 801 analyzer, alone or integrated into an artificial intelligence model, as an early, reliable, and routinely usable biomarker for the diagnosis of septic Disseminated Intravascular Coagulation.",[259,260,261],"Disseminated Intravascular Coagulation (DIC)","Reanimation","Septic Shock","2026-06-01",{"date":121,"type":38},{"date":96,"type":22},{"date":266,"type":22},"2029-01-15",{"name":44,"class":45},{"id":269,"slug":270,"hasResults":12,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":274,"eligibilityCriteria":275,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":276,"targetDuration":4,"studyType":23,"phases":278,"briefSummary":279,"conditions":280,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":285,"completionDateStruct":286,"leadSponsor":288,"locationsCount":77},"100637417","tedlar-bag-stability-of-volatile-sulfur-compounds-for-remote-halitosis-diagnosis-100637417","NCT07602309","Tedlar Bag Stability of Volatile Sulfur Compounds for Remote Halitosis Diagnosis","Relevance of Using Tedlar Bags for the Remote Evaluation of the Stability of Volatile Sulfur Compounds in Gaseous Samples for the Diagnosis of Halitosis","Malodorix","Inclusion Criteria:\n\nAdult subject, male or female\n\n* Subject affiliated with a health insurance system\n* Subject able to sign the non-opposition form\n* Subject attending a consultation at UF8607 for diagnosis and treatment of a periodontal condition\n\nExclusion Criteria:\n\n* \\- Subject under legal protection (judicial safeguard)\n* Subject under guardianship or curatorship\n* Pregnancy or breastfeeding\n* Inability to provide the subject with informed information (e.g., emergency situation, comprehension difficulties)\n* Subject currently enrolled in another clinical research protocol or in an exclusion period",{"count":277,"type":22},100,[25],"Halitosis, or bad breath, affects about 30% of people worldwide and is most often caused by oral diseases such as periodontitis. To diagnose it, dentists usually perform a clinical examination and measure specific gases in the breath called volatile sulfur compounds (VSCs), which are responsible for bad odor. However, the equipment needed for this analysis is not widely available, forcing many patients to travel long distances. This study aims to determine whether breath samples can be collected and analyzed later, making remote diagnosis possible. Specifically, it evaluates whether the levels of these gases remain stable for up to 7 days after collection, with a variation of less than 20% considered acceptable. To do this, 100 adult patients with periodontal conditions will be included in a single-center study.\n\nDuring a single visit, patients will provide breath samples by exhaling into a special Tedlar bag and a syringe, which will then be analyzed immediately and again after 7 days using a device called OralChroma. Afull periodontal examination will also be performed, and patient information such as age and risk factors will be collected. The study will also examine how gas levels change over time and whether they are linked to gum disease. If the results confirm that the samples remain stable, this approach could allow patients to collect their breath at home and receive a diagnosis remotely, reducing the need for travel and improving access to care.",[281,282],"Halitosis","Periodontal Diseases","2026-05-29",{"date":239,"type":38},{"date":262,"type":22},{"date":287,"type":22},"2027-06-01",{"name":44,"class":45},{"id":290,"slug":291,"hasResults":12,"nctId":292,"briefTitle":293,"officialTitle":293,"acronym":294,"eligibilityCriteria":295,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":296,"targetDuration":4,"studyType":23,"phases":298,"briefSummary":299,"conditions":300,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":77},"100637289","phase-4-evaluation-of-the-efficacy-of-sublingual-sufentanil-prescribed-as-rescue-analgesia-for-acute-postoperative-pain-on-the-quality-of-health-recovery-after-surgery-a-randomized-controlled-multicenter-open-label-trial-against-an-active-comparator-sublime-100637289","NCT07624006","Evaluation of the Efficacy of Sublingual Sufentanil (Prescribed as Rescue Analgesia for Acute Postoperative Pain) on the Quality of Health Recovery After Surgery: a Randomized, Controlled, Multicenter, Open-label Trial Against an Active Comparator (SUBLIME)","SUBLIME","Inclusion Criteria:\n\nAged 18 years or older (with no upper age limit) Undergoing surgery in a surgical department of the participating centers for a procedure whose usual postoperative management includes the prescription of an oral rescue opioid analgesic Able to provide informed consent Affiliated with a health insurance\u002Fsocial security system or beneficiary of such a system\n\nExclusion Criteria:\n\nKnown hypersensitivity to the components of Sublingual sufentanil 30 µg Known hypersensitivity to the components of Morphine sulfate Compromised respiratory function, such as decompensated respiratory failure or respiratory depression Severe hepatic insufficiency (i.e., with encephalopathy) Severe renal insufficiency (GFR \\\u003C 30) Acute head trauma with intracranial hypertension Uncontrolled epilepsy Ileus Patients receiving daily preoperative treatment with opioids such as morphine, sufentanil, fentanyl, oxycodone, buprenorphine, nalbuphine, methadone, naltrexone, nalmefene, or sodium oxybate Pregnant or breastfeeding women Incapacitated individuals (subject to legal protection measures: judicial protection, curatorship, guardianship, future protection mandate, or family authorization) Inability to administer the mQoR-15f questionnaire (cognitive impairment, language barrier) or inability to provide informed information to the subject (emergency situations, subject's comprehension difficulties, etc.)",{"count":297,"type":22},1150,[232],"The number of surgical procedures performed annually exceeds 300 million worldwide and continues to grow. The management of the most common perioperative symptoms (pain, nausea\u002Fvomiting, constipation) represents a major public health challenge.\n\nIn the context of postoperative pain management, a multimodal analgesia strategy is recommended in order to minimize opioid consumption. The opioid currently most commonly used is oral morphine sulfate. New therapeutic options are emerging, including sublingual sufentanil (Dzuveo®, 30 µg), which combines opioid-like effects with a faster onset of action due to its lipophilicity.\n\nThe hypothesis of this study is that, because of its unique pharmacokinetic and pharmacodynamic profile, this new formulation is more effective than oral morphine sulfate in the treatment of postoperative pain and in the recovery of health status.",[301],"Postoperative Pain","2026-05-28",{"date":239,"type":38},{"date":305,"type":22},"2027-01-01",{"date":307,"type":22},"2030-02-28",{"name":44,"class":45},{"id":310,"slug":311,"hasResults":12,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":315,"eligibilityCriteria":316,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":317,"enrollmentInfo":318,"targetDuration":4,"studyType":23,"phases":320,"briefSummary":322,"conditions":323,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":4},"100604643","phase-2-study-comparing-antipsychotic-dose-reduction-vs-maintenance-treatment-in-patients-with-schizophrenia-spectrum-disorder-a-personalized-medicine-approach-100604643","NCT07152184","Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patients With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach","A Prospective, Randomized, and Controlled Study Comparing Two Treatment Strategies (Dose REduction of Antipsychotics vs. Maintenance Treatment) in Patients With Schizophrenia Spectrum Disorder After Stratification Based on Patients' Psychotic PHENotype: a Personalized Medicine Approach","DREAMS-Phen","Inclusion Criteria:\n\n* \\- Patient 18-60 years of age;\n* Patient affiliated to health insurance (beneficiary or beneficiary's family);\n* Patient informed of the results of the preliminary medical examination;\n* Patient able to understand the aims and risks of the research (assisted by his\u002Fher curator, if applicable (if subject under curatorship\\*))\n* Informed consent signed by patient\n* Patient with a diagnosis of schizophrenia spectrum disorder (SSD): schizophrenia, schizophreniform, schizoaffective disorder or brief psychotic episode according to DSM-5;\n* Patient with:\n\n  1. Either a cycloid psychosis (CP) phenotype according to By-CP (score \\>=80%)\n  2. Or another (non-CP) psychotic phenotype; (By-CP score \\\u003C 80%)\n* Outpatient followed by an ambulatory psychiatrist;\n* Patient with an identified caregiver, defined as a person able to support the patient for the duration of the study, spending at least 8 hours per week with the patient or having easy access to the patient per phone.\n* Patient clinically stabilized, for at least 6 months, as defined by\n\n  a) low intensity of positive symptoms, i.e. PANSS P1, P2 and P3 items \\\u003C 4.\n* Patient treated with oral antipsychotics (in mono or polytherapy, with second- or first-generation antipsychotics);\n* Patients with a PSP score \\>70 at baseline will also be included\n* The participant agrees to follow the contraceptive requirements detailed in the protocol \\*Subjects under limited guardianship (i.e. French \"curatelle\") can participate to the study.\n\nExclusion Criteria:\n\n* \\- Patient hospitalized in a psychiatric ward;\n* Patient with a recent psychotic episode (during the last 6 months);\n* Patient treated with long-acting injection of antipsychotics (due to feasibility constraints and to the fact that these treatments remain essentially proposed to non-compliant patients with high risk of acute cessation and loss to follow-up);\n* Patient treated with clozapine (in mono or polytherapy - highly resistant patients, specificities of the relapses under clozapine\n* Patient considered by his psychiatrists to be at serious risk of harm to self or others (e.g. previous aggressive or suicidal behaviors); notably, a patient answering \"yes\" to C-SSRS suicidal ideation Type 4 or 5, having any suicidal behavior assessment within 6 months at Screening, or having been hospitalized or treated for suicidal behavior in the past 5 years before Screening. The investigator will rely on the results of the C-SSRS questionnaire completed at the time of inclusion (after consent has been signed) or previously completed as part of the patient's follow-up according to current practice.\n* Neurological or severe medical condition other than psychosis;\n* Pregnancy (verified by urinary test at enrollment for women of childbearing potential);\n* Current breastfeeding;\n* Patient involved in another Investigational Medicinal Product trial or having participated in another investigational drug trial, in which they received the investigational drug, within 60 days\n* Patient in an exclusion period defined by another research protocol;\n* Patient under guardianship (i.e. French 'tutelle');\n* Patient with care under constraint\n* Patients deprived of freedom because of a judicial measure.\n* Inability to give the patient the written consent form (emergency situation)\n* Patients with major depressive disorder (CDSS \\> 5) or manic episode (DSM-5-TR)\n* Patients with any of the following signs of substance abuse:\n\n  1. Current diagnosis or history of substance use disorder and\u002For substance intoxication as defined in the DSM-5-TR. If the history of substance use disorder is more than 12 months before baseline, the participant may be allowed to enroll in the trial after consultation with the sponsor (Participant must also have negative urine drug screen at the screening.)\n  2. A positive urine screen for drugs of abuse at screening.\n  3. A history of alcohol consumption exceeding 2 standard drinks per day on average (1 glass is approximately equivalent to the following: beer \\[354 mL\u002F12 oz\\], wine or sake \\[118 mL\u002F4 oz\\], or distilled spirits \\[29.5 mL\u002F1 oz\\] per day).\n  4. A positive Breathalyzer test for alcohol at screening. The investigator will screen urine for drug abuse and perform an alcohol test at the inclusion visit (after consent has been signed), and may also rely on previous results obtained in the course of patient follow-up according to standard practice.\n* The participant is a trial site employee, a site employee's immediate family member (for example, spouse, parent, child, sibling), or is in a dependent relationship with a site employee who is involved in conduct of this trial or may consent under duress.","60 Years",{"count":319,"type":22},288,[321],"PHASE2","The objective of this study is to respond to frequent requests from patients who wish to reduce or even stop their antipsychotic treatment once they have achieved clinical stability. Psychiatrists are reluctant to respond to these requests because the method for safely reducing or stopping antipsychotic treatment remains poorly understood.\n\nThe investigators want to verify the existence of an interaction between treatment strategy and psychotic phenotype (cycloid psychosis vs. non-CP), i.e., in terms of functional remission, the benefit of the dose reduction strategy compared to the maintenance strategy will be greater in the CP group than in the non-CP group.\n\nTo this end, patients will be randomly assigned to four groups based on their phenotype and treatment strategy (CP-dose reduction; CP-dose maintenance; non-CP-dose reduction; and non-CP-dose maintenance).\n\nSeveral hospitals throughout France are participating in this study, in which a random draw (called randomization) will be conducted to determine whether the physician will propose reducing the antipsychotic dose or maintaining it at the same dose for the patient.\n\nPatients included in this study will be adults aged 18 to 60 who have been diagnosed with a schizophrenic spectrum disorder (SS): schizophrenia, schizophreniform disorder, schizoaffective disorder, or brief psychotic episode.\n\nThe antipsychotics studied are:\n\n* second-generation antipsychotics: amisulpride, aripiprazole, olanzapine, quetiapine, risperidone;\n* first-generation antipsychotics: chlorpromazine, flupentixol, haloperidol, levomepromazine, loxapine, pipotiazine, zuclopenthixol.\n\n  288 patients will be included and followed for 24 months. The inclusion period is 48 months.\n\nFourteen follow-up visits are planned, every month for four months and then every two months. During these visits, self-questionnaires or cognitive tests will have to be completed by the patient, the caregiver, and\u002For the treating psychiatrist.\n\nThree blood samples will be taken at inclusion, at 6 months, and at the end of the study, in particular to measure the level of medication in the blood.",[324,325,326],"Patient With Schizophrenia Spectrum Disorder","NLM Classification WM 203, Psychology:Schizophrenic Psychology","Schizophrenia Spectrum and Other Psychotic Disorders","2026-05-22",{"date":329,"type":38},"2026-05-26",{"date":331,"type":22},"2026-10-01",{"date":333,"type":22},"2032-02-01",{"name":44,"class":45},{"id":336,"slug":337,"hasResults":12,"nctId":338,"briefTitle":339,"officialTitle":339,"acronym":340,"eligibilityCriteria":341,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":342,"targetDuration":4,"studyType":23,"phases":344,"briefSummary":345,"conditions":346,"keywords":352,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":363,"locationsCount":77},"100584513","timing-of-anticoagulant-administration-during-radial-access-percutaneous-coronary-intervention-the-hera-pci-study-heparin-early-for-radial-access-percutaneous-coronary-intervention-100584513","NCT06890312","Timing of Anticoagulant Administration During Radial Access Percutaneous Coronary Intervention: the HERA-PCI Study (Heparin Early for Radial Access Percutaneous Coronary Intervention)","HERA-PCI","Inclusion Criteria:\n\n* Patients having 18 years old or older, regardless of gender, undergoing percutaneous radial coronary intervention\n* Subject affiliated to a social protection health insurance\n* Subject able to understand the objectives and risks of the research and to provide dated and signed consent\n* Subject who has been informed of the results of the preliminary medical examination\n\nExclusion Criteria:\n\n* Contraindication to the use of heparin (history of heparin-induced thrombocytopenia)\n* Very high bleeding risk defined by recent bleeding (\\\u003C6 months) of type 3 of the BARC classification\n* Subject in an exclusion period (determined by a previous or ongoing study)\n* Inability to give the subject enlightened information (subject in an emergency situation, difficulties in understanding the subject, etc.)\n* Subject under safeguard of justice\n* Subject under guardianship or curatorship\n* Pregnancy\n* Breastfeeding\n* Patient on anticoagulant treatment: anti-vitamin K, direct oral anticoagulants (DOACs).",{"count":343,"type":22},550,[25],"While the reduced hemorrhagic risk of radial access for percutaneous coronary intervention compared to femoral access is well-established, its main complication remains radial artery occlusion, which can occur in up to 30% of patients. Anticoagulation is the primary preventive measure recommended in clinical practice to reduce the risk of this complication, typically involving heparin injection during the procedure in most centers. However, data on the effect of the timing of heparin injection are limited. The investigators hypothesize that injection of heparin before sheath insertion may reduce the rate of radial artery occlusion compared with injection after sheath insertion.",[347,348,349,350,351],"Coronary Angiography","Percutaneous Coronary Intervention","Radial Artery Occlusion","Bleeding","Anticoagulation",[353,354,355,356,357],"Anticoagulant injection timing","Percutaneous coronary intervention","Coronary angiography","Radial artery occlusion prevention","Bleeding events","2026-05-20",{"date":329,"type":38},{"date":361,"type":38},"2025-06-05",{"date":195,"type":22},{"name":44,"class":45},{"id":365,"slug":366,"hasResults":12,"nctId":367,"briefTitle":368,"officialTitle":368,"acronym":369,"eligibilityCriteria":370,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":371,"targetDuration":4,"studyType":23,"phases":373,"briefSummary":374,"conditions":375,"keywords":377,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":380,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":386},"100575400","phase-3-evaluation-of-the-efficacy-of-oral-immunotherapy-with-raw-apple-in-patients-allergic-to-birch-pollen-and-apple-prospective-multicenter-comparative-phase-iii-study-100575400","NCT06771791","Evaluation of the Efficacy of Oral Immunotherapy With Raw Apple in Patients Allergic to Birch Pollen and Apple: Prospective, Multicenter, Comparative Phase III Study","ELIO","Inclusion Criteria:\n\n* Patient with allergic rhinitis to birch pollen.\n* Patient with an oral syndrome within 15 minutes of consuming at least one of the first 3 doses of raw apple in the V0 or V1 raw apple oral challenge test.\n* Evidence of sensitization to PR10 proteins in birch pollen and apple: positive prick tests to birch pollen and raw Golden apple and\u002For positive Bet v 1 and Mal d 1 specific IgE assays.\n* Subject affiliated to a social health insurance scheme\n* Subject able to understand the aims and risks of the research and to give dated and signed informed consent\n* For women of childbearing age: negative urine pregnancy test at inclusion visit\n\nExclusion Criteria:\n\n* Severe or uncontrolled asthma\n* Severe obstructive syndrome\n* Active neoplastic disease\n* Active autoimmune disease\n* Eosinophilic esophagitis or other active eosinophilic gastrointestinal pathologies\n* History of bariatric surgery\n* History of anaphylaxis to apples\n* Allergy to cooked apples\n* Contraindication to anti-histamines, corticoids, salbutamol, adrenaline\n* Other contraindication to an oral challenge test\n* Allergy to placebo ingredients\n* Presence of oral syndrome during consumption of placebo in the first oral challenge test\n* Allergenic immunotherapy to birch pollen in progress or completed less than 5 years ago\n* Current treatment with anti-IgE, anti-IL4\u002F13, anti-IL5 or anti-TSLP biotherapy.\n* Impossibility of giving the subject informed information\n* Subject under court protection\n* Subject under guardianship or curatorship\n* Pregnancy",{"count":372,"type":22},110,[180],"Apple-birch pollen-food allergy syndrome is particularly common in Northern and Central Europe (70% of patients allergic to birch pollen), and classically induces an oral syndrome that impairs patients' quality of life. Current treatment is based on food avoidance. However, evidence of the efficacy of this treatment is limited (small numbers, lack of validation with a control group, absence of double-blind evaluation of the primary endpoint in a challenge test against placebo). The aim of oral immunotherapy with raw apple is to improve the management of allergic patients by enabling them to acquire tolerance to raw apple and other rosacea.",[376],"Allergies",[378,379],"allergy","oral immunotherapy",{"date":329,"type":38},{"date":382,"type":38},"2025-01-08",{"date":384,"type":22},"2027-05-05",{"name":44,"class":45},4,{"id":388,"slug":389,"hasResults":12,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":393,"eligibilityCriteria":394,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":395,"targetDuration":4,"studyType":23,"phases":397,"briefSummary":398,"conditions":399,"keywords":404,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":386},"100592873","long-read-genome-sequencing-for-the-molecular-diagnosis-of-dystonia-100592873","NCT06999096","Long-read Genome Sequencing for the Molecular Diagnosis of Dystonia","Evaluation of the Value of Long-read Genome Sequencing for the Molecular Diagnosis of Dystonia: a Prospective Multicenter Study","GenoDYT","Inclusion criteria - Index case:\n\n* Index case affected by familial dystonia (≥1 first-degree relative affected) and\u002For sporadic early-onset dystonia (symptom onset before age 50), meeting the criteria of the PFMG-2025 program.\n* Index case who has undergone short-read genome sequencing, which did not lead to a molecular diagnosis.\n* Ability to understand and sign informed consent by the index case and\u002For their parents or legal guardians for patients under 18 years of age.\n* Availability of a blood sample from the index case and at least two relatives, either affected or unaffected.\n\nInclusion criteria - Relatives:\n\n* Symptomatic or asymptomatic relative of an index case, who has also undergone short-read genome sequencing without a conclusive molecular diagnosis.\n* Ability to understand and sign informed consent.\n\nExclusion criteria:\n\n* Index case or relatives who are not affiliated with or not beneficiaries of a social security scheme.\n* Index case and their parents presenting with a condition that, in the opinion of the investigator, would contraindicate participation in the study.\n* Suspected non-genetic etiology (e.g., perinatal hypoxic-ischemic injury, kernicterus, history of severe head trauma or central nervous system infection).",{"count":396,"type":22},150,[25],"Dystonia is a motor disorder caused by involuntary, intermittent, or sustained muscle contractions, leading to abnormal movements or postures. It can affect any body region and often results in significant functional disability and healthcare burden. Although its familial nature was recognized early on, the advent of high-throughput DNA sequencing has dramatically increased the identification of dystonia-associated genes. Dystonia now encompasses all modes of inheritance-autosomal dominant (e.g., TOR1A, KMT2B), autosomal recessive, X-linked, and mitochondrial-and over 100 genes have been implicated. Many forms involve structural variants (SVs) or copy number variations (CNVs), which are challenging to detect using standard short-read sequencing (srWGS).\n\nMolecular diagnosis is essential, ending the diagnostic odyssey and enabling genetic counseling, prognosis, reproductive planning, and-in some cases-targeted therapies. For instance, GNAO1-related dystonia may respond to deep brain stimulation, while dopa-responsive dystonia benefits from levodopa.\n\nDespite advances, srWGS has key limitations, especially for detecting repeat expansions, SVs, and phasing alleles. This likely explains the low diagnostic yield in dystonia compared to other neurological disorders, with over 70% of cases remaining unsolved.\n\nLong-read sequencing (lrWGS), such as Oxford Nanopore technology, overcomes many of these challenges by reading native DNA fragments thousands of bases long. It enables comprehensive detection of SNVs, indels, SVs, CNVs, methylation changes, and repeat expansions-including known and newly discovered pathogenic expansions (e.g., in NOTCH2NLC). It also allows phasing without parental samples, which is crucial in recessive cases.\n\nThe investigators propose that lrWGS could significantly increase the diagnostic yield in dystonia, improving patient care, enabling appropriate genetic counseling, and paving the way for personalized treatment strategies.",[400,401,402,403],"Dystonia","Movement Disorders","Combined Dystonia","Complex Dystonia",[400,405,406,407,408],"Genome Sequencing","Long-read Sequencing","Molecular diagnosis","Neurogenetics","2026-05-19",{"date":358,"type":38},{"date":412,"type":22},"2026-04-22",{"date":414,"type":22},"2030-08",{"name":44,"class":45},{"id":417,"slug":418,"hasResults":12,"nctId":419,"briefTitle":420,"officialTitle":4,"acronym":4,"eligibilityCriteria":421,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":422,"targetDuration":4,"studyType":256,"phases":4,"briefSummary":424,"conditions":425,"keywords":4,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":77},"100239647","orodental-manifestations-of-rare-diseases-100239647","NCT02397824","Orodental Manifestations of Rare Diseases","Inclusion Criteria:\n\n* Patient presenting with a rare disease\n\n  * New patient or patient already known in the center\n  * Child (in his primary dentition) or adult\n  * Man or woman\n  * Having signed a consent form or accepted to participate to the study\n  * Patient affiliated to social security\n  * Validation of the inclusion by the principal investigator looking at the patient file\n\nExclusion Criteria:\n\n* Patient whose clinical diagnostic is not possible\n\n  * Patient whose clinical file does not contain teeth photos\n  * Patient who has not signed a consent form and accepted to participate to the study\n  * Patient who is not affiliated to social security.\n  * Non validation of the inclusion by the principal investigator looking at the patient file",{"count":423,"type":22},1300,"OroDental anomalies are one of the phenotypical aspects of at least 900 rare diseases or syndromes affecting by definition less than 1 in 2000 individual within the population (almost 25 million persons in Europe).\n\nThey are often described in association with other organs or system malformations, which is understandable, because the same genes and signalling pathways regulate the oral cavity formation or odontogenesis and the development of other organs. The various dental and orofacial anomalies can be classified by type (anomalies of tooth number, shape, size, structures of mineralized tissues, eruption, resorption, tumors; anomalies of oral mucosa; anomalies of tongue…), by signalling pathways and by syndrome families.\n\nThese anomalies (for example hypodontia\u002Foligodontia, amelogenesis imperfecta, dentinogenesis imperfecta…) become increasingly identified as diagnostic and predictive traits. Not only is it important to recognise, name appropriately and integrate these dysmorphic clues into the patient dysmorphology analysis but it is essential to synthesize the observations and confront them to existing data about similar orodental anomalies encountered in some of the corresponding mutant mouse models.\n\nTranslational approaches in development and medicine, are relevant to gain understanding of molecular events underlying clinical manifestations and to enhance diagnostic accuracy.\n\nThe aim of this study is to improve the knowledge, diagnosis and care of oral cavity pathologies encountered in rare diseases via the identification and gathering of national and international patient cohorts and to structure the molecular diagnosis behind these conditions via targeted next-generation sequencing assays. Data collection is implemented on validated accredited tools (databases) complying with the legal regulations about patient data protection and medical record collection. All information is anonymized.\n\nNew effective diagnosis and therapeutic tools are being developed.",[426],"Rare Disease Orodontal","2026-05-12",{"date":429,"type":38},"2026-05-15",{"date":431,"type":38},"2015-01",{"date":433,"type":22},"2035-12",{"name":44,"class":45},{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":441,"eligibilityCriteria":442,"healthyVolunteers":137,"sex":443,"minAge":18,"maxAge":444,"enrollmentInfo":445,"targetDuration":4,"studyType":23,"phases":447,"briefSummary":448,"conditions":449,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":453,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":4},"100583055","perimenstrual-symptoms-and-emotional-dysregulation-in-autism-100583055","NCT06871345","Perimenstrual Symptoms and Emotional Dysregulation in Autism","Evaluation of the Links Between Perimenstrual Symptoms and Emotional Dysregulation in Autistic Individuals: Ecological, Subjective, and Cognitive Approach","MEDEA","Inclusion criteria:\n\nCommon Inclusion Criteria for Healthy Patients and Volunteers:\n\n* Female aged 18 to 45;\n* Woman with regular menstrual cycles (variations in duration, measured between the shortest menstrual cycle) and the longest cycle, remain strictly less than 7 days) between 25 and 35 days;\n* Woman without hormonal contraception (or NON-hormonal copper IUD) or who has stopped contraception for more than 3 months (and does not wish to take it again);\n* Woman with a smartphone with an internet connection;\n* Woman able to understand the objectives and risks of the research and to give informed, dated and signed consent;\n* Woman affiliated to a social protection health insurance scheme, beneficiary or beneficiary.\n\nPatient-specific inclusion criteria:\n\n* Specific inclusion criteria for female patients\n* Patient with a diagnosis of Autism Spectrum Disorder without intellectual disability (ASD), according to DSM-5 criteria OR\n* Patient with a diagnosis of BPD, according to DSM-5 criteria OR\n* Patient meeting the diagnostic criteria for PMDD with the SCID\n\nExclusion criteria:\n\nNon-inclusion criteria common to healthy patients and volunteers:\n\n* Taking hormonal treatment or synthetic steroids;\n* Woman using hormonal contraceptives (pill, patch, hormonal IUD, vaginal ring, implant, intramuscular injection);\n* Pregnancy or breastfeeding on the declaration of the person for less than 3 months;\n* Desire to become pregnant within 3 months of inclusion;\n* Endocrinopathies (in particular clinical signs of hyperandrogenism) or untreated gynaecological pathologies that may influence menstrual cycles and\u002For ovulation;\n* Participation in another study that may interfere with the study;\n* Inability to give the person informed information (person in an emergency or life-threatening situation);\n* Woman under judicial protection;\n* Woman under guardianship or curatorship;\n* Woman hospitalized for a period \\> 24 hours\n\nPatient-specific non-inclusion criteria:\n\n* Patient with a diagnosis of psychotic disorder;\n* Patient with a diagnosis of severe substance use disorder, i.e., presence of 6 or more symptoms;\n* Patient with a diagnosis of bipolar disorder type I or II or cyclothymia;\n* Patient with a diagnosis of co-occurring ASD and BPD;\n* Patient with an intellectual disability (IQ ≤ 70);\n* Patient with neurological comorbidity (e.g., acquired brain injury);\n* Patient on treatment that alters physiological response (heart rhythm, e.g., beta-blockers).\n\nNon-inclusion criteria specific to healthy volunteers:\n\n\\- Woman with a psychiatric, neurodevelopmental, or neurological history;","FEMALE","45 Years",{"count":446,"type":22},90,[25],"Emotional dysregulation (ED) is defined by difficulties in modulating the experience and expression of emotions, which are characterized by particularly marked reactivity, intensity, and duration. To improve the understanding of ED, its consequences in autistic women, and to be able to offer them appropriate treatments, it seems crucial to investigate the links between ED, known adversities during childhood, and premenstrual dysphoric symptoms. This study aims to characterize the variability of ED throughout a menstrual cycle by measuring it in an ecological real-life context. The variability of ED will be compared to that of women with borderline personality disorder (BPD), women with premenstrual dysphoric disorder (PMDD), and women without a diagnosed disorder.",[450,451,452],"Autism Spectrum Disorder","Borderline Personality Disorder BPD","a Premenstrual Dysphoric Disorder (PMDD)",{"date":427,"type":38},{"date":455,"type":22},"2026-05-01",{"date":457,"type":22},"2029-07-01",{"name":44,"class":45},{"id":460,"slug":461,"hasResults":12,"nctId":462,"briefTitle":463,"officialTitle":464,"acronym":465,"eligibilityCriteria":466,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":467,"targetDuration":4,"studyType":256,"phases":4,"briefSummary":468,"conditions":469,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":475,"leadSponsor":477,"locationsCount":77},"100638787","fluorescent-leukocytes-as-a-marker-of-early-sepsisseverity-100638787","NCT07585942","Fluorescent Leukocytes as a Marker of Early Sepsis\u002FSeverity","NEUTROPHIL FLUORESCENCE AS AN EARLY BIOMARKER OF SEPSIS SEVERITY IN THE EMERGENCY DEPARTMENT","FLAMES","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Admission to the ED\n* Suspected or proven infection defined by the prescription of antibiotic therapy within 24 hours following admission to the ED\n* Collection of an EDTA blood sample as part of routine care\n* Patient informed and has not expressed opposition\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Legal protection measure (guardianship, curatorship, judicial protection)",{"count":255,"type":22},"Sepsis is a medical emergency whose prognosis depends on the early identification of patients at risk of septic shock, but the tools available in the Emergency Department remain insufficient. Neutrophils, key players in immunothrombosis, show alterations detectable via cell fluorescence (e.g., NE-SFL), which are strongly correlated with the severity of sepsis and septic DIC. The FLAMES study will evaluate, from the time of admission to the Emergency Department, the relevance of neutrophil fluorescence as an early biomarker of severity, either alone or integrated into an AI model based on the multiparametric data from the SthemA 801, with comparison to the Sysmex XN. It aims to address an unmet clinical need: the immediate stratification of the risk of severe forms of sepsis. Hypothesis: higher initial fluorescence will identify patients at risk of organ failure, septic shock, or DIC.",[470,259,261],"Sepsis","2026-05-06",{"date":473,"type":38},"2026-05-14",{"date":427,"type":22},{"date":476,"type":22},"2027-12-12",{"name":44,"class":45},{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":482,"acronym":483,"eligibilityCriteria":484,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":485,"targetDuration":4,"studyType":256,"phases":4,"briefSummary":487,"conditions":488,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":498,"locationsCount":77},"100636077","internuclear-ophthalmoplegia-and-multiple-sclerosis-a-multicenter-retrospective-study-100636077","NCT07560995","Internuclear Ophthalmoplegia and Multiple Sclerosis: a Multicenter Retrospective Study","INO&MS","Inclusion criteria:\n\n* Patients with internuclear ophthalmoplegia listed as a primary or associated diagnosis\n* Patients hospitalized in a neurology department\n\nExclusion criteria:\n\n\\- Patients under 18 years of age",{"count":486,"type":22},200,"Internuclear ophthalmoplegia is a symptom frequently associated with multiple sclerosis (MS), although other etiologies are possible. Some patients do not meet the diagnostic criteria for MS at the time of the internuclear ophthalmoplegia episode but subsequently convert to MS. Studying this specific clinical situation may help enable earlier diagnosis of MS.\n\nThe objective is to analyze the proportion of patients with isolated internuclear ophthalmoplegia who convert to multiple sclerosis and to identify factors associated with this conversion.\n\nThe study hypothesis is that the presence of internuclear ophthalmoplegia is highly suggestive of multiple sclerosis, particularly when cerebrospinal fluid-specific oligoclonal bands are present.",[489,490],"Multiple Sclerosis","Internuclear Ophthalmoplegia","2026-05-04",{"date":493,"type":38},"2026-05-08",{"date":495,"type":22},"2026-05",{"date":497,"type":22},"2027-05",{"name":44,"class":45},{"id":500,"slug":501,"hasResults":12,"nctId":502,"briefTitle":503,"officialTitle":504,"acronym":505,"eligibilityCriteria":506,"healthyVolunteers":137,"sex":17,"minAge":18,"maxAge":317,"enrollmentInfo":507,"targetDuration":4,"studyType":23,"phases":508,"briefSummary":509,"conditions":510,"keywords":513,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":523,"lastUpdatePostDateStruct":524,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":529,"locationsCount":77},"100636095","effects-of-repetitive-transcranial-magnetic-stimulation-on-two-cerebellar-targets-100636095","NCT07561229","Effects of Repetitive Transcranial Magnetic Stimulation on Two Cerebellar Targets","Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) on Two Cerebellar Targets (Lobule VIII vs. CRUS I\u002FII)","StimCervelet","Inclusion Criteria:\n\n* Subject, male or female, aged between 18 and 60 years inclusive\n* Subject affiliated with or a beneficiary of a social security health insurance scheme\n* Subject has dated and signed the informed consent form prior to the start of any trial-related procedures\n* For women of childbearing potential, a negative urinary pregnancy test and the use of effective contraception throughout the duration of the study\n\nExclusion Criteria:\n\n* Subject with substance use disorders (as defined by the DSM-5)\n* Subject having taken benzodiazepines and related compounds (within the period preceding inclusion, for a duration equivalent to 5 half-lives of the product), cannabis (within the 2 months preceding inclusion), or hallucinogenic substances (within the period preceding inclusion, for a duration equivalent to 5 half-lives of the product)\n* Subject suffering from a neurological pathology or sequelae\n* Subject with Attention-Deficit\u002FHyperactivity Disorder (ADHD)\n* Subject with Borderline Personality Disorder\n* Subject presenting with disabling sensory impairments, specifically a visual acuity (corrected, if applicable) \\\u003C 0.8 (due to the use of visual materials; Freiburg Vision Test, Bach 1996; verified during an examination at the screening visit)\n* Subject deprived of liberty or under legal protection\n* Subject under guardianship or trusteeship\n* Pregnant or breastfeeding woman (verified by a urinary test at the screening visit)\n* Subject within an exclusion period defined by another clinical study or participating in a study likely to impact the results of the research\n* Subject presenting a contraindication for fMRI or rTMS: presence of non-removable ferromagnetic bodies, prostheses, pacemakers, implanted medication pumps, vascular clips or stents, heart valves or ventricular shunts, certain intracerebral clips, cochlear implants, history of seizures (epilepsy), or skin breach\u002Fpathology at the point of contact with the electrodes\n* Subject with a history of major neurological or psychiatric disease with current psychotropic medication (i.e., antipsychotics, benzodiazepines and related compounds, or hypnotics)",{"count":56,"type":22},[25],"The purpose of this study is to understand how different areas of the cerebellum (a part of the brain) control different functions and how they can be influenced by non-invasive brain stimulation.\n\nWhile researchers know that repetitive Transcranial Magnetic Stimulation (rTMS) can have positive effects on conditions like stroke and schizophrenia, they do not yet fully understand which specific stimulation settings work best or which exact parts of the cerebellum should be targeted for different symptoms.\n\nThis study compares the effects of stimulation on two specific regions:\n\n* Lobule VIII: Linked to movement and motor learning.\n* CRUS I\u002FII: Linked to attention, thinking (cognition), and predicting the timing of events.By comparing these areas, researchers hope to gain the information needed to develop better treatments for neurological and psychiatric disorders.\n\nThis is a randomized, double-blind study involving 40 healthy volunteers. Participants will be split into two groups:\n\n* Group 1: Receives \"exciting\" (activity-increasing) stimulation.\n* Group 2: Receives \"inhibiting\" (activity-decreasing) stimulation.\n\nEach participant will attend three different test sessions in a random order:\n\n* rTMS targeting Lobule VIII\n* rTMS targeting CRUS I\u002FII\n* Placebo (Sham) stimulation that looks and feels like the real thing but does not affect the brain.\n\nDuring each session, researchers will use brain imaging (fMRI) and computerized tasks to measure changes in brain connectivity and performance in motor and cognitive activities.\n\nThere is no direct medical benefit to the participants. However, the results will help scientists create better therapies for patients with brain-related health issues The risks are considered minimal. Common side effects of rTMS include temporary mild headaches or a clicking sound during stimulation. MRI scans can sometimes cause mild discomfort or a feeling of closed-in spaces (claustrophobia). Researchers have put safety measures in place, such as hearing protection and constant medical supervision during scans, to minimize these risks.",[511,512],"Healthy","Healthy Adult",[514,515,516,517,518,519,520,521,522],"Repetitive Transcranial Magnetic Stimulation (rTMS)","Cerebellum","Lobule VIII","Crus I\u002FII","Resting-state functional Magnetic Resonance Imaging (rs-fMRI)","Neuromodulation","Neuroplasticity","Excitatory vs. Inhibitory Stimulation","Neurotypical","2026-04-27",{"date":455,"type":38},{"date":526,"type":22},"2026-09-01",{"date":528,"type":22},"2030-01-02",{"name":44,"class":45},{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":534,"acronym":535,"eligibilityCriteria":536,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":537,"enrollmentInfo":538,"targetDuration":4,"studyType":23,"phases":540,"briefSummary":541,"conditions":542,"keywords":545,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":553,"startDateStruct":554,"completionDateStruct":555,"leadSponsor":557,"locationsCount":558},"100634915","multicenter-prospective-study-analyzing-the-occurrence-of-multiple-sclerosis-relapses-without-radiological-evidence-myth-or-reality-100634915","NCT07545889","Multicenter Prospective Study Analyzing the Occurrence of Multiple Sclerosis Relapses Without Radiological Evidence: Myth or Reality?","MYTH-MS","Inclusion Criteria:\n\n* Adult aged 18 to 70 years.\n* Relapsing-Remitting Multiple Sclerosis according to the McDonald 2024 criteria.\n* Patient receiving disease-modifying therapy (DMT) for multiple sclerosis.\n* Most recent EDSS score between 0 and 7.0, dating back less than 1 year.\n* Patient presenting with a neurological exacerbation lasting more than 24 hours and less than 7 days (excluding fatigue and pain alone).\n* Patient capable of understanding the objectives and risks associated with the study and who has provided informed consent.\n* Patient affiliated with or a beneficiary of a social security health insurance scheme.\n\nExclusion Criteria:\n\n* Primary progressive or secondary progressive multiple sclerosis.\n* Diagnosis of chronic psychotic disorder.\n* Infection within the past week.\n* Body temperature \\> 38.5°C at V0 (baseline visit).\n* Corticosteroid bolus or plasma exchange in the month preceding inclusion.\n* Chronic treatment with corticosteroids or immunosuppressants for another pathology.\n* Contraindication to MRI or gadolinium.\n* Uncontrolled cardiac, renal, or hepatic pathology.\n* Patient participating in another interventional study or still within an exclusion period.\n* Pregnant or breastfeeding woman.\n* Severe claustrophobia.\n* Patient deprived of liberty (e.g., incarcerated).","70 Years",{"count":539,"type":22},136,[25],"The MYTH-MS study is a multicenter prospective study investigating the occurrence of clinical relapses in patients with relapsing-remitting multiple sclerosis (RRMS) in the absence of radiological activity on MRI.\n\nWhile MS relapses are typically associated with gadolinium-enhancing lesions on MRI, some patients present with acute neurological symptoms without radiological correlates, referred to as acute clinical events with stable MRI (ACES). The frequency, mechanisms, and clinical relevance of these events remain unclear due to limitations in previous studies.\n\nThe primary objective is to determine the proportion of RRMS patients experiencing a relapse without gadolinium-enhancing lesions on early brain and spinal MRI. Secondary objectives include identifying clinical, radiological, biological, and psychological predictors, assessing neurologists' diagnostic accuracy, and evaluating clinical outcomes such as disability, cognition, and quality of life over a 6-month follow-up.\n\nA total of 136 patients with recent neurological exacerbations will be included. Each participant will undergo clinical assessment, cognitive and psychological evaluation, and early MRI, with follow-up at 6 months. An ancillary study will explore blood biomarkers (NfL, GFAP, and circulating DNA) to help differentiate true inflammatory relapses from ACES.\n\nThis study aims to improve the understanding and diagnosis of MS exacerbations and to optimize patient management by reducing misdiagnosis and unnecessary treatments.",[489,543,544],"RRMS","Multiple Sclerosis (MS) - Relapsing-remitting",[489,546,547,548,549,550,551],"Relapsing-Remitting Multiple Sclerosis","Acute Clinical Events with Stable MRI (ACES)","Gadolinium-enhancing lesions","MRI-negative relapse","Functional Neurological Disorder","Pseudo-relapse","2026-04-15",{"date":412,"type":38},{"date":526,"type":22},{"date":556,"type":22},"2030-05-01",{"name":44,"class":45},8,{"id":560,"slug":561,"hasResults":12,"nctId":562,"briefTitle":563,"officialTitle":563,"acronym":564,"eligibilityCriteria":565,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":566,"targetDuration":4,"studyType":23,"phases":568,"briefSummary":569,"conditions":570,"keywords":577,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":585,"startDateStruct":586,"completionDateStruct":587,"leadSponsor":589,"locationsCount":77},"100634918","single-arm-monocentric-pilot-feasibility-study-on-an-interactive-virtual-reality-program-in-20-complex-in-clinic-palliative-care-patients-100634918","NCT07545928","Single Arm, Monocentric, Pilot Feasibility Study on an Interactive Virtual Reality Program in 20 Complex In-clinic Palliative Care Patients","ZENCTUARY_VR+","Inclusion Criteria:\n\n* Patient ≥ 18 years old, hospitalized at the USP - HUS\n* Estimated life expectancy ≥ 1 month (Pronopall score based on clinical data).\n* Montreal Cognitive Assessment (MoCA) scale score ≥ 26.\n* Able to understand the objective and risks of the study\n* VRISE score ≤ 25 after the VR familiarization procedure\n* Affiliation with the Social Security system or beneficiary of such social protection.\n* Signed consent from, able to understand and complete the questionnaires in French.\n\nExclusion Criteria:\n\n* Patients with psychiatric disease\n* Patients under court protection\n* Uncontrolled epilepsy\n* Visual impairments (lack of binocular vision, blindness) and\u002For hearing impairments (deafness) preventing the use of virtual reality",{"count":567,"type":22},20,[25],"Palliative care patients frequently face a \"symptom cluster\" of pain (up to 96%), fatigue (up to 90%), and anxiety (up to 79%), which severely degrades their quality of life in their final months.The study is built on the concept of passive exposure therapy (VREP), which engages multiple senses to distract the brain from pain signals. By creating an \"immersive distraction\" or a \"flow state,\" VR can activate the brain's reward networks and reduce activity in areas associated with pain perception. Unlike most existing VR research in palliative care which uses \"passive\" VR (like watching a 360-degree video), this study uses interactive VR. Patients can perform simple actions-like grabbing or dropping virtual objects-within a calming natural environment, which may better support their sense of autonomy and dignity. Because this is a pilot study, the \"Go\u002FNo-Go\" decision for future larger trials depends on a strict composite of three factors:\n\n* Adherence: The patient must complete at least 11 out of 14 planned daily sessions.\n* Duration: Each session must average at least 7.5 minutes of usable VR exposure.\n* Tolerance: The patient must experience no device-related serious adverse events and maintain a high average tolerance score (VRISE score ≥ 25).",[571,572,573,574,575,576],"Palliative Care","Refractory Pain","Anxiety","Depression Disorders","Fatigue, Mental","Psychological Distress",[578,579,580,581,582,583,584],"palliative care","end-of-life care","refractory pain","Interactive Virtual Reality","Immersive Technology","Virtual Reality Exposure Therapy (VRET)","Cybersickness in Palliative Care",{"date":412,"type":38},{"date":526,"type":22},{"date":588,"type":22},"2027-03-01",{"name":44,"class":45},{"id":591,"slug":592,"hasResults":12,"nctId":593,"briefTitle":594,"officialTitle":594,"acronym":595,"eligibilityCriteria":596,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":597,"targetDuration":4,"studyType":23,"phases":599,"briefSummary":600,"conditions":601,"keywords":602,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":608,"lastUpdatePostDateStruct":609,"startDateStruct":611,"completionDateStruct":612,"leadSponsor":614,"locationsCount":77},"100630516","phase-3-assessing-the-efficacy-of-dapagliflozin-as-a-vasculoprotective-treatment-in-septic-shock-patients-with-microcirculatory-dysfunction-100630516","NCT07488689","Assessing the Efficacy of Dapagliflozin as a Vasculoprotective Treatment in Septic Shock Patients With Microcirculatory Dysfunction","GLIFLOSHOCK","Inclusion Criteria:\n\n1. Patient aged ≥ 18 years\n2. Hospitalized in ICU for septic shock according to Sepsis-3 definition (PMID: 26903338). Septic shock should be the primary reason for admission.\n3. Septic shock diagnosed for less than 12 hours prior to randomization\n4. Skin mottling (mottling score ≥ 2) according to Ait-Oufella and\u002For prolonged capillary refill time \\> 3 seconds\n5. Patient benefiting from social health insurance (or having a close relative who is a beneficiary)\n6. Patient or legal representative having signed an informed consent to participate in the study. In case immediate consent is not possible, an emergency procedure will be applied in accordance with current regulations\n\nExclusion Criteria:\n\n1. Patient in whom oral administration is not possible at the initial stage (e.g., emergency digestive surgery, acute mesenteric ischemia, etc.).\n2. Patient treated with SGLT2 inhibitor before ICU admission\n3. Hypoglycemia \\\u003C 0.5 g\u002FL (2.75 mmol\u002FL)\n4. End-stage kidney disease undergoing maintenance dialysis\n5. Medical history of type 1 diabetes (gliflozins are not authorized for treatment of this type of diabetes)\n6. Medical history of diabetic ketoacidosis\n7. Ongoing Fournier's gangrene\n8. Current treatment with lithium\n9. Cirrhose child C\n10. Do not resuscitate order at inclusion in the study\n11. Concomitant participation in another interventional therapeutic trial\n12. Patient deprived of liberty or under legal protection (guardianship, conservatorship, or legal protection)\n13. Pregnancy or breastfeeding\n14. Contraindications to dapagliflozin",{"count":598,"type":22},568,[180],"Microcirculatory dysfunction is a key driver of organ failure and mortality in septic shock, characterized by endothelial injury and impaired vasoregulation. Despite its strong prognostic value, it remains unaddressed by current therapies. SGLT-2 inhibitors (SGLT-2i) have shown promising vasculoprotective, anti-inflammatory, and glucose-lowering effects that may help restore endothelial function, reduce vascular leakage, and manage stress-induced hyperglycemia-factors central to septic shock pathophysiology. Preclinical and clinical observational studies suggest potential benefits, but clinical research in this specific context is lacking. This trial aims to evaluate the efficacy and safety of SGLT-2i in septic shock patients with clinical signs of microcirculatory failure, addressing a critical unmet medical need.\n\nSeptic shock management relies on rapid infection control, hemodynamic stabilization with fluids and vasopressors, and supportive care, with corticosteroids used in select cases. However, this standardized approach faces major limitations due to patient heterogeneity, treatment-related complications (e.g., fluid overload, vasopressor side effects), and rising antimicrobial resistance. Adjunctive therapies have largely failed to improve outcomes, reflecting the complex pathophysiology of septic shock. These challenges highlight a pressing need for novel, targeted interventions and a shift toward personalized treatment strategies.\n\nThe investigators hypothesize that early administration of SGLT-2 inhibitors within 14 hours of septic shock onset in patients showing signs of microcirculatory dysfunction will improve 28-day outcomes mainly by targeting endothelial and microvascular injury. Expected benefits include reduced mortality and organ dysfunction, faster recovery with lower resource use, a favorable safety profile, and potential for global implementation as a cost-effective adjunctive therapy.\n\nThis study will be a multicenter, prospective, randomized, and comparative double-blind trial. All patients admitted with septic shock in the ICU will be screened for trial eligibility criteria.\n\nAfter verifying the eligibility criteria and obtaining patient or family consent, or after an emergency inclusion procedure, eligible patients will be randomized in a 1:1 ratio to receive either Dapagliflozin (10 mg once daily) or matching placebo in addition to standard-of-care.\n\nPatients will be followed up for 1 year or until death, whichever occurs first.",[261],[603,604,605,606,607],"microcirculatory dysfunction","septic shock","dapagliflozin","SGLT-2i","gliflozins","2026-03-23",{"date":610,"type":38},"2026-03-27",{"date":40,"type":22},{"date":613,"type":22},"2030-07",{"name":44,"class":45},{"id":616,"slug":617,"hasResults":12,"nctId":618,"briefTitle":619,"officialTitle":620,"acronym":621,"eligibilityCriteria":622,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":623,"targetDuration":625,"studyType":256,"phases":4,"briefSummary":626,"conditions":627,"keywords":4,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":629,"lastUpdatePostDateStruct":630,"startDateStruct":632,"completionDateStruct":634,"leadSponsor":636,"locationsCount":77},"100629126","study-of-glucose-tolerance-abnormalities-using-continuous-glucose-monitoring-for-the-identification-of-early-loss-of-pancreatic-islet-graft-function-100629126","NCT07470593","Study of Glucose Tolerance Abnormalities Using Continuous Glucose Monitoring for the Identification of Early Loss of Pancreatic Islet Graft Function.","Prospective Longitudinal Observational Study of Glucose Tolerance Abnormalities Using Continuous Glucose Monitoring for the Identification of Early Loss of Pancreatic Islet Graft Function.","ISLET-TITR","Inclusion Criteria:\n\n* ≥18 years old\n* Insulin-dependent diabetes (type 1 diabetes, secondary to chronic pancreatitis, MODY, cystic fibrosis)\n* Patient who has completed a full cycle of pancreatic islet transplantation, either:\n\n  * Islet Transplantation Alone (ITA), or\n  * Islet After Kidney (IAK), or\n  * Simultaneous Islet Kidney (SIK), with \\>10,000 IEQ\u002Fkg of recipient body weight, or \\\u003C10,000 IEQ\u002Fkg but having achieved insulin independence\n* Patient who has provided consent for reuse of their data for this research\n\nExclusion Criteria:\n\n* Patient refusal to wear continuous glucose monitoring device\n* Pancreatic islet autotransplantation\n* Inability to provide informed consent (e.g., difficulties understanding study information)\n* Patient under judicial protection (safeguard of justice)\n* Patient under guardianship or curatorship",{"count":624,"type":22},36,"1 Year","Islet transplantation is associated with drastically improvement glucose control in people with type 1 diabetes. This treatment resulted in the disappearance of severe hypoglycemic events. However, its long-term effectiveness is limited by progressive loss of graft function. Currently, there is no standardized method to detect early dysfunction of the transplanted islets.\n\nThis study aims to determine whether a parameter derived from continuous glucose monitoring (CGM), Time in Tight Range (70-140 mg\u002FdL), is associated with pancreatic islet grafts function.\n\nThe study hypothesis is that a decrease in Time in Tight Range reflects early loss of islet graft function.",[628],"Type 1 Diabetes (T1D)","2026-03-13",{"date":631,"type":38},"2026-03-17",{"date":633,"type":38},"2025-12-15",{"date":635,"type":22},"2029-12-15",{"name":44,"class":45},{"id":638,"slug":639,"hasResults":12,"nctId":640,"briefTitle":641,"officialTitle":641,"acronym":642,"eligibilityCriteria":643,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":644,"targetDuration":4,"studyType":23,"phases":646,"briefSummary":647,"conditions":648,"keywords":652,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":657,"lastUpdatePostDateStruct":658,"startDateStruct":660,"completionDateStruct":662,"leadSponsor":663,"locationsCount":77},"100357965","fatigue-and-skeletal-muscle-impact-in-severe-axial-spondyloarthritis-100357965","NCT03940911","Fatigue and Skeletal Muscle Impact in Severe Axial Spondyloarthritis","Famuspa","Inclusion criteria:\n\n* Axial SA according to the ASAS criteria;\n* Targeted therapy naïve patients\n* Indication to start a targeted therapy;\n* Initiation of targeted therapy ≤ 15 days before inclusion\n* ≥ 18 years old, no upper age limit;\n* Subject affiliated to a social health insurance reimbursement;\n* Subject able to understand the aims and risks of the research and having signed a dated and informed consent\n* Subject informed of the results of the preliminary medical examination\n* Woman in childbearing age: negative beta-HCG test and effective contraception;\n* Sufficient understanding of French to follow the protocol.\n\nExclusion criteria:\n\n* Targeted therapy in progress for \\> 15 days prior to inclusion\n* Contraindication to the use of targeted therapy\n* Systemic corticosteroids in the 15 days preceding the V0 visit\n* Associated extramuscular inflammatory disease (s) (excluding ocular and cutaneous involvement) eg chronic inflammatory bowel disease\n* Associated fibromyalgia (Questionnaire score FiRST ≥5) achieved during the V0 visit\n* History of coronary artery disease: exercise angina, acute coronary syndrome and \u002F or coronary angioplasty,\n* History of lower extremity arterial disease: vascular claudication and \u002F or lower extremity angioplasty\n* COPD\n* Neuromuscular pathology\n* Insufficiency of organ (renal, hepatic pulmonary heart)\n* Sleep apnea\n* Impossibility of giving the subject informed information (subject in emergency situation, difficulties in understanding the subject, etc.)\n* Subject under the protection of justice\n* Subject under guardianship or curatorship\n* Breastfeeding\n* Pregnancy\n* Subject in exclusion period defined by another clinical study or participating in a study likely to impact the results of the research",{"count":645,"type":22},122,[25],"Axial spondyloarthropathy (SpA) is the most common inflammatory rheumatism (1% of the general population) with important medico-economic consequences.\n\nFatigue is a major feature of SA. It can be defined as a feeling of reduced muscle capacity, lack of energy and exhaustion. The fatigue reaches an abnormally high level (fatigue severity score (FSS) ≥4, called severe fatigue in this protocol) in more than two thirds of patients with SA.\n\nSkeletal muscle repercussions are present during SA. It is characterized by a decrease in exercise capacity independently of pain and ankylosis but is associated with a decrease in strength and muscle mass, the importance of which varies from one study to another.\n\nThe link between fatigue (subjective sensation) and the skeletal muscular impact (objective) of SA has never been studied.",[649,650,651],"Spondyloarthritis, Axial","Fatigue","Exercise Capacity",[653,650,654,655,656],"Axial spondylarthritis","Targeted therapy","Exercise capacity","Sarcopenia","2026-03-09",{"date":659,"type":38},"2026-03-12",{"date":661,"type":38},"2025-11-13",{"date":219,"type":22},{"name":44,"class":45},""]